Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism

Circulation

Volumn 135, Issue 4, 2017, Pages 338-351

  Watts, Gerald F ^a   Chan, Dick C ^b   Dent, Ricardo ^c   Somaratne, Ransi ^c   Wasserman, Scott M ^c   Scott, Rob ^c   Burrows, Sally ^b   Barrett, P Hugh R ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c AMGEN INC   (United States)

Author keywords

AMG 145; atorvastatin calcium; lipoproteins; metabolism

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; CAMPESTEROL; CHOLESTEROL ESTER; EVOLOCUMAB; INTERMEDIATE DENSITY LIPOPROTEIN; LATHOSTEROL; LEUCINE; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE 9; VERY LOW DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; FACTORIAL DESIGN; HUMAN; INSULIN RESISTANCE; LIPID ABSORPTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ATORVASTATIN CALCIUM; DOUBLE-BLIND METHOD; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85007206567     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.025080     Document Type: Article

References (37)

1. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, 2016 ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis 2016 253 281 344
2. Dietschy JM, Turley SD, Spady DK, Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993 34 1637 1659
3. Barrett PH, Chan DC, Watts GF, Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans. J Lipid Res 2006 47 1607 1619. doi: 10.1194/jlr.R600017-JLR200
4. Chan DC, Barrett PH, Watts GF, The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Pract Res Clin Endocrinol Metab 2014 28 369 385. doi: 10.1016/j.beem.2013.10.001
5. Seidah NG, Awan Z, Chrétien M, Mbikay M, PCSK9: a key modulator of cardiovascular health. Circ Res 2014 114 1022 1036. doi: 10.1161/CIRCRESAHA.114.301621
6. Giugliano RP, Sabatine MS, Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 2015 65 2638 2651. doi: 10.1016/j.jacc.2015.05.001
7. Stein EA, Raal F, Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014 65 417 431. doi: 10.1146/annurev-med-022613-090402
8. Grundy SM, Statins: definitive translational research. Mol Med 2014 20 suppl 1 S20 S23. doi: 10.2119/molmed.2014.00194
9. Ooi EM, Barrett PH, Chan DC, Nestel PJ, Watts GF, Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis 2008 197 139 146. doi: 10.1016/j.atherosclerosis.2007.03.004
10. Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG, Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J Clin Endocrinol Metab 2002 87 2283 2289. doi: 10.1210/jcem.87.5.8455
11. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG, Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003 52 803 811
12. Colbert A, Umble-Romero A, Prokop S, Xu R, Gibbs J, Pederson S, Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum. MAbs 2014 6 1103 1113. doi: 10.4161/mabs.28719
13. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB, Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988 29 1149 1155
14. Grundy SM, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988 319 24 33. doi: 10.1056/NEJM198807073190105
15. Csete ME, Doyle JC, Reverse engineering of biological complexity. Science 2002 295 1664 1669. doi: 10.1126/science.1069981
16. Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM, Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol 1996 16 794 801
17. Dong B, Wu M, Cao A, Li H, Liu J, Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression. Int J Mol Med 2011 27 103 110. doi: 10.3892/ijmm.2010.559
18. Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K, Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways. Arterioscler Thromb Vasc Biol 2014 34 1171 1178. doi: 10.1161/ATVBAHA.113.302670
19. Watts GF, Naoumova RP, Kelly JM, Riches FM, Croft KD, Thompson GR, Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997 273 3 pt 1 E462 E470
20. Blasiole DA, Oler AT, Attie AD, Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB. J Biol Chem 2008 283 11374 11381. doi: 10.1074/jbc.M710457200
21. Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M, Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004 24 1448 1453. doi: 10.1161/01.ATV.0000133684.77013.88
22. Cariou B, Ouguerram K, Zaïr Y, Guerois R, Langhi C, Kourimate S, Benoit I, Le May C, Gayet C, Belabbas K, Dufernez F, Chétiveaux M, Tarugi P, Krempf M, Benlian P, Costet P, PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009 29 2191 2197. doi: 10.1161/ATVBAHA.109.194191
23. Bilheimer DW, Stone NJ, Grundy SM, Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo. J Clin Invest 1979 64 524 533. doi: 10.1172/JCI109490
24. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL, Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988 8 1147 1150
25. Watts GF, Chan DC, Barrett PH, O'Neill FH, Thompson GR, Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord 2003 27 862 865. doi: 10.1038/sj.ijo.0802287
26. Thompson GR, Naoumova RP, Watts GF, Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996 37 439 447
27. Krieger M, Herz J, Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994 63 601 637. doi: 10.1146/annurev.bi.63.070194.003125
28. Mahley RW, Ji ZS, Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999 40 1 16
29. Ooi EM, Barrett PH, Chan DC, Watts GF, Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008 114 611 624. doi: 10.1042/CS20070308
30. Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH, Atorvastatin and fenofibrate have comparable effects on VLDL-Apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008 28 1831 1837. doi: 10.1161/ATVBAHA.108.170530
31. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG, The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008 283 2363 2372. doi: 10.1074/jbc.M708098200
32. Curtiss LK, Boisvert WA, Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000 11 243 251
33. Ooi EM, Ng TW, Watts GF, Chan DC, Barrett PH, Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. J Lipid Res 2012 53 2443 2449. doi: 10.1194/jlr.P029223
34. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS, PROFICIO Investigators Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014 35 2249 2259. doi: 10.1093/eurheartj/ehu085
35. Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S, Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and-independent mechanisms. Circulation 2014 130 431 441. doi: 10.1161/CIRCULATIONAHA.113.006720
36. Ooi EM, Barrett PH, Watts GF, The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies. Int J Cardiol 2013 168 1811 1818. doi: 10.1016/j.ijcard.2013.06.069
37. Druce I, Abujrad H, Ooi T, PCSK9 and triglyceride-rich lipoprotein metabolism. J Biomed Res 2015 29 429 436